乌帕替尼诱导治疗223例克罗恩病的有效性与安全性:一项GETAID多中心队列研究
这项法国GETAID多中心回顾性队列研究纳入2022年9月至2024年6月接受乌帕替尼45 mg每日一次诱导治疗的223例难治性管腔型克罗恩病患者,评估第12周无激素临床缓解(SFCR)等结局。结果显示SFCR为107/197(54%),临床反应129/197(65%),临床缓解111/197(56%),生物标志物缓解90/173(52%),内镜和/或影像学反应18/38(47%)。58例(26%)发生65例不良事件,包括17例严重不良事件,安全性可接受。
要点
- 第12周无激素临床缓解(SFCR)为107/197(54%),临床反应129/197(65%)。
- 生物标志物缓解90/173(52%),内镜和/或影像学反应18/38(47%)。
- 58例(26%)发生65例不良事件,包括17例严重不良事件。
核心结论
- 在这组高度难治的克罗恩病患者中,乌帕替尼诱导治疗使约三分之二患者获得临床反应、半数患者获得无激素临床缓解,安全性可接受。
研究设计与样本
- 法国GETAID 29个中心开展的多中心回顾性队列研究,连续纳入2022年9月至2024年6月接受乌帕替尼45 mg每日一次治疗的难治性管腔型克罗恩病患者223例。
主要发现
- 223例患者均既往暴露于至少一种生物制剂(中位4种,IQR [3, 4]),119例(53.8%)有既往肠切除史。
- 第12周时,无激素临床缓解为107/197(54%),临床反应为129/197(65%),临床缓解为111/197(56%)。
- 生物标志物缓解为90/173(52%);内镜和/或影像学反应为18/38(47%)。
- 肠外表现临床反应为37/47(79%),肠外表现临床缓解为29/47(62%)。
- 58例患者(26%)共发生65例不良事件,包括17例严重不良事件、16例疾病加重和1例结肠EBV相关淋巴增殖性疾病;痤疮24/223(11%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Real-world effectiveness and safety of upadacitinib in patients with Crohn's disease (CD) remain unclear. AIMS: This study aimed to evaluate the effectiveness and safety of upadacitinib in a real-world cohort. METHODS: From September 2022 to June 2024, all consecutive patients with refractory luminal CD treated with once daily upadacitinib 45 mg in 29 French GETAID centres were retrospectively included. The primary outcome was steroid-free clinical remission (SFCR) at week 12, defined as a Harvey-Bradshaw Index (HBI) of < 4. Clinical response (decrease of ≥ 3 points in HBI and/or HBI < 4), clinical remission, biomarker remission, endoscopic and/or radiologic response and safety were also assessed. RESULTS: Among the 223 patients included, all were previously exposed to at least one biologic (median 4, IQR [3, 4]) and 119 (53.8%) had prior intestinal resection. At week 12, SFCR was achieved in 107/197 (54%), clinical response in 129/197 (65%) and clinical remission in 111/197 (56%). A total of, 90 out of 173 (52%) achieved biomarker remission. Endoscopic and/or radiologic response was observed in 18/38 (47%) patients. Clinical response of extraintestinal manifestations was observed in 37/47 (79%) patients and clinical remission in 29/47 (62%). A total of, 65 adverse events (AEs) occurred in 58 patients (26%), including 17 serious AEs, 16 disease exacerbation and one case of colonic EBV-associated lymphoproliferative disorder. Acne was reported in 24/223 (11%) patients. CONCLUSION: In this real-world cohort of highly refractory CD patients, upadacitinib induction resulted in a clinical response in about two-thirds of patients and in SFCR in half of the patients, with an acceptable safety profile.
引用
- Richard N, Amiot A, Seksik P, et al. Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients With Crohn's Disease: A GETAID Multicentre Cohort Study. Aliment Pharmacol Ther. 2025. PMID: 40038887. doi:10.1111/apt.70073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。